{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:20:27Z","timestamp":1792718427310,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00296-019-04272-1","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T13:02:40Z","timestamp":1553778160000},"page":"1083-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases"],"prefix":"10.1007","volume":"39","author":[{"given":"Jens","family":"Vikse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Terje","family":"Kval\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wildhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"Omdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"issue":"3","key":"4272_CR1","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"4272_CR2","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69(9):1629\u20131635","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4272_CR3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","volume":"74","author":"RB Jones","year":"2015","unstructured":"Jones RB, Furuta S, Tervaert JW et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74(6):1178\u20131182","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4272_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221\u2013232","journal-title":"N Engl J Med"},{"issue":"4","key":"4272_CR5","first-page":"468","volume":"28","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Garc\u00eda-Hern\u00e1ndez FJ, de Ram\u00f3n E et al (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28(4):468\u2013476","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"4272_CR6","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology 49(9):1683\u20131693","journal-title":"Rheumatology"},{"key":"4272_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2017.05.002","volume":"182","author":"GM Verstappen","year":"2017","unstructured":"Verstappen GM, Van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H (2017) The value of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome. Clin Immunol 182:62\u201371","journal-title":"Clin Immunol"},{"issue":"11","key":"4272_CR8","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","volume":"25","author":"F Catapano","year":"2010","unstructured":"Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW (2010) Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transpl 25(11):3586\u20133592","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4272_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al (2014) Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med 160(4):233\u2013242","journal-title":"Ann Intern Med"},{"issue":"1","key":"4272_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4272_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215\u20131226","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4272_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ost\u00f6r AJ (2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 51(4):653\u2013662","journal-title":"Rheumatology"},{"issue":"7","key":"4272_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/10428190902934944","volume":"50","author":"R Ram","year":"2009","unstructured":"Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P (2009) The late adverse events of rituximab therapy\u2014rare but there! Leuk Lymphoma 50(7):1083\u20131095","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"4272_CR14","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF Vollenhoven Van","year":"2013","unstructured":"Van Vollenhoven RF, Emery P, Bingham CO et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496\u20131502","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4272_CR15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven Van","year":"2015","unstructured":"Van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761\u20131766","journal-title":"J Rheumatol"},{"issue":"1","key":"4272_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfx378","volume":"34","author":"SP McAdoo","year":"2019","unstructured":"McAdoo SP, Medjeral-Thomas N, Gopaluni S et al (2019) Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transpl 34(1):63\u201373","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"4272_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"F Keyser De","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41(9):1761\u20131765","journal-title":"J Rheumatol"},{"issue":"6","key":"4272_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","volume":"57","author":"AGS Oldroyd","year":"2018","unstructured":"Oldroyd AGS, Symmons DPM, Sergeant JC et al (2018) Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology 57(6):1089\u20131096","journal-title":"Rheumatology"},{"issue":"6","key":"4272_CR19","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE Daalen Van","year":"2017","unstructured":"Van Daalen EE, Rizzo R, Kronbichler A et al (2017) Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 76(6):1064\u20131069","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4272_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/03009742.2016.1241298","volume":"46","author":"J Vikse","year":"2016","unstructured":"Vikse J, Rygh A, Kaisen K, Omdal R (2016) Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin. Scand J Rheumatol 46(5):413\u2013414","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"4272_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54(2):613\u2013620","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4272_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/08916934.2014.914174","volume":"47","author":"N Venhoff","year":"2014","unstructured":"Venhoff N, Niessen L, Kreuzaler M et al (2014) Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity 47(6):401\u2013408","journal-title":"Autoimmunity"},{"issue":"10","key":"4272_CR23","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1136\/ard.2008.091124","volume":"67","author":"TY Lu","year":"2008","unstructured":"Lu TY, J\u00f3nsd\u00f3ttir T, Van Vollenhoven RF, Isenberg DA (2008) Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. Ann Rheum Dis 67(10):1493\u20131494","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4272_CR24","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","volume":"56","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Barnard J, Owen T et al (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044\u20133056","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4272_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909\u2013920","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4272_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/acr.22921","volume":"69","author":"R Aguiar","year":"2016","unstructured":"Aguiar R, Ara\u00fajo C, Martins-Coelho G, Isenberg D (2016) Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken) 69(2):257\u2013262","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04272-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04272-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:15:56Z","timestamp":1585268156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04272-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4272"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04272-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JV\u00a0has received honorarium from Novartis for participation in advisory board. RO\u00a0has received honorarium from Roche for lectures and participation in advisory board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}